EU/3/18/2013

Table of contents

About

On 16 April 2018, orphan designation (EU/3/18/2013) was granted by the European Commission to Roche Registration Limited, United Kingdom, for polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma.

The sponsorship was transferred to Roche Registration GmbH., Germany, in July 2018.

Key facts

Active substance
polatuzumab vedotin
Disease / condition
Treatment of diffuse large B-cell lymphoma
Date of decision
16/04/2018
Outcome
Positive
Orphan decision number
EU/3/18/2013

Sponsor's contact details

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Tel. +49 (0) 7624 142892
E-mail: global.eu_regulatory_office@roche.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating